TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05588141: 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Sponsor: National Cancer Institute (NCI) · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 96 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT05588141 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05588141 Rescue Dossier →